OAR 333-008-1785: Inhalable Cannabinoid Product Processing Site Requirements

(1) A processing site may only use a non-cannabis additive in an inhalable cannabinoid product if the non-cannabis additive is accompanied by a list of ingredients from the manufacturer of the non-cannabis additive that: (a) In a header section, displays the name of the non-cannabis additive and the business name of the manufacturer of the non-cannabis additive; (b) In clear and legible font, includes a statement that the non-cannabis additive is for use in a product intended for human inhalation; (c) Accurately identifies all ingredients in the non-cannabis additive; and (d) For each ingredient of the non-cannabis additive, includes: (A) A Chemical Abstracts Service Reference Number that specifies the ingredient’s isomer and, if applicable, enantiomer; and (B) The ingredient’s concentration range within 20 percentage points. (2) A processing site may not use a non-cannabis additive in an inhalable cannabinoid product that contains any amount of: (a) Squalene; (b) Squalane; (c) Vitamin E Acetate; (d) Triglycerides, including but not limited to Medium-Chain Triglyceride (MCT) Oil; or (e) Propylene Glycol, unless the product is going to be delivered through a metered dose inhaler whose functionality does not require combustion or heated vaporization. (3) A processing site in possession of an inhalable cannabinoid product with non-cannabis additives must: (a) Record the item in CTS with the item category of "Inhalable Cannabinoid Product with Non-Cannabis Additives". (b) In the item’s ingredients section of CTS record: (A) The name of all non-cannabis additives used in the items; and (B) For each non-cannabis additive used, the business name of the manufacturer of the non-cannabis additive. (c) The ingredients recorded in CTS under subsection (3)(b) if this rule must match the information that is contained in the header section of the non-cannabis additive’s list of ingredients as required under subsection (1)(a) of this rule. (4) A processing site may not manufacture or process an inhalable cannabinoid product that does not meet the requirements of this rule. (5) A processing site may not possess, sell, deliver, transfer, transport, purchase, or receive an inhalable cannabinoid product that does not meet the requirements of this rule.